Publications by authors named "Clara Armengol Tubau"
Dermatol Ther (Heidelb)
July 2023
Article Synopsis
- Atopic dermatitis (AD) is a chronic skin condition with few treatment options for teens, and lebrikizumab, an antibody targeting IL-13, shows potential benefits in treating it, based on previous studies.
- The Phase 3 ADore study involved 206 adolescents with moderate-to-severe AD, who received lebrikizumab and were monitored for safety and effectiveness over 52 weeks.
- Out of 172 participants who completed the study, many experienced improvements, such as 65% achieving significant reductions in disease severity, while serious side effects were infrequent, indicating the treatment's promise for managing AD in adolescents.
